Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

GSK faces criminal bribery investigation in Poland
Reuters
Monday, April 14, 2014 - 8:40am
tags:
GSK, bribery, Pioland
Deadly Bowel Infection Draws Drugmakers Seeking Cures
Bloomberg
Monday, April 14, 2014 - 8:37am
tags:
Merck, Sanofi, Actelion, Shire, Clostridium Difficile
Price of New Hepatitis C Drugs Not So Daunting After All
Bloomberg
Monday, April 14, 2014 - 8:35am
tags:
drug pricing, hepatitis C, Sovaldi, Gilead Sciences
Oncolytics Biotech reports evaluation of clinical study with REOLYSIN
The Fly on the Wall
Monday, April 14, 2014 - 8:26am
tags:
Oncolytics, Reolysin, hepatitis B, hepatitis C, liver cancer
Pfizer Vs. Eli Lilly, Novartis In Breast Cancer Race
Seeking Alpha
Monday, April 14, 2014 - 8:20am
tags:
Novartis, Pfizer, Eli Lilly, breast cancer, palbociclib, Faslodex, AstraZeneca, LY2835219, LEE011
Lexicon Pharmaceuticals up 25% on drug trial
Marketwatch
Monday, April 14, 2014 - 8:14am
tags:
Lexicon Pharmaceuticals, type 1 diabetes, LX4211
Got Allergies? FDA to the Rescue
Motley Fool
Sunday, April 13, 2014 - 10:17am
tags:
Stallergenes, allergies, Merck, Grastek
This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
Motley Fool
Sunday, April 13, 2014 - 10:14am
tags:
Questcor, MannKind, Agios Pharmaceuticals, Mallinckrodt, Alkermes, Merck
This Firm's Patented Technology Could Unlock A $5 Billion Market
Yahoo/Street Authority
Sunday, April 13, 2014 - 10:12am
tags:
Actinium Pharmaceuticals, cancer
FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon?
The Street
Saturday, April 12, 2014 - 10:27am
tags:
Novartis, Zykadia, ceritinib, lung cancer
Can This Drug Be a Game Changer for Eli Lilly?
Motley Fool
Saturday, April 12, 2014 - 10:25am
tags:
Eli Lilly, bemaciclib, breast cancer
Encouraging Data from Bristol-Myers
Yahoo/Zacks
Saturday, April 12, 2014 - 10:20am
tags:
Bristol-Myers Squibb, HCV, hepatitis, hepatitis C, daclatasvir, asunaprevir
Let's Get the Facts Straight About Zohydro ER--and the Important Patient Need It Fills
Yahoo/PR NewsWire
Saturday, April 12, 2014 - 10:19am
tags:
Zohydro, Zogenix, pain management, opiods
AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress
Yahoo/PR NewsWire
Saturday, April 12, 2014 - 10:15am
tags:
hepatitis, hepatitis C, AbbVie, Ribavirin
Encouraging Results on Gilead's Sovaldi
Yahoo/Zacks
Saturday, April 12, 2014 - 10:13am
tags:
Gilead Sciences, Sovaldi, HCV, hepatitis, hepatitis C
CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Six Month Warrants
Yahoo/BusinessWire
Saturday, April 12, 2014 - 10:12am
tags:
Cel-Sci
Are Celgene and Amgen Undervalued By the Market?
Motley Fool
Saturday, April 12, 2014 - 10:11am
tags:
Amgen, Celgene
3 Drugs Stocks Driving The Industry Higher
TheStreet.com
Friday, April 11, 2014 - 3:41pm
tags:
Celgene, Merck, Gilead Sciences
Arena - Belviq Sales Up Modestly Heading Into Television Ads
Seeking Alpha
Friday, April 11, 2014 - 3:40pm
tags:
drug ads, Belviq, Eisai, Arena Pharmaceuticals
Texas Medicaid holds off on proposed limits for Gilead hepatitis drug
Yahoo/Reuters
Friday, April 11, 2014 - 3:38pm
tags:
Texas, Gilead Sciences, Medicaid, hepatitis C, Sovaldi

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.